ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Net Change in Cash history
Currency unavailable · from the cash flow
No Net Change in Cash data reported for this period type.
Net Change in Cash vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $301.55M USD | +384.7% | — | 420.0% | |
| LTM Mar 2026 | $116.23M USD | -220.5% | +11.8% | 362.3% | |
| LTM Mar 2026 | $81.23M USD | -9.2% | — | — | |
| LTM Mar 2026 | $60.43M USD | -15.4% | — | 133.2% | |
| LTM Mar 2026 | $59.21M USD | — | +49.3% | 6425.7% | |
| LTM Mar 2026 | €53.17M EUR | -213.8% | -24.9% | 395.5% | |
| LTM Mar 2026 | $28.14M USD | +1537.1% | — | 697.6% | |
| LTM Mar 2026 | $5.19M USD | +110.1% | +19.1% | 6.5% | |
| FY2025 | $0 USD | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -9.2% | +15.5% | 378.9% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.